Brevan Howard Capital Management’s United Therapeutics UTHR Stock Holding History

Brevan Howard Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.26M	Buy	+4,174	New	+$2.35M	0.02%	666
2026 Q1	–	Sell	-4,454	Closed	-$2.17M	–	2515
2025 Q4	$2.17M	Buy	4,454 +1,573	+55%	+$733K	0.02%	461
2025 Q3	$1.21M	Sell	2,881 -557	-16%	-$187K	0.01%	811
2025 Q2	$988K	Buy	+3,438	New	+$1.03M	0.01%	1066
2024 Q3	–	Sell	-3,529	Closed	-$1.12M	–	1454
2024 Q2	$1.12M	Buy	+3,529	New	+$934K	0.01%	338

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Brevan Howard Capital Management's UTHR Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in United Therapeutics (UTHR) in Q2 2026: 4,174 shares worth $2.26M. The stake represents 0.02% of the portfolio and ranks #666 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in UTHR as recently as Q4 2025.

Brevan Howard Capital Management first reported a position in UTHR in Q2 2024 and has held it in 5 quarters since. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Brevan Howard Capital Management held 4,174 shares of United Therapeutics worth $2.26M as of Q2 2026.
United Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
United Therapeutics made up 0.02% of Brevan Howard Capital Management's portfolio in Q2 2026, its #666 holding.
Brevan Howard Capital Management first reported a position in United Therapeutics in Q2 2024 and has held it in 5 quarters since.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.